Showcasing Impactful Research and Collaborations in Personalised Medicine
The EP PerMed success stories highlight the remarkable achievements and outcomes of projects funded under the European Research Area Network, ERA-Net ERA PerMed, and EP PerMed initiative. These stories demonstrate the tangible impact of research in personalised medicine, from groundbreaking scientific discoveries to advancements in clinical practice, innovative methodologies, and collaborations that drive progress in healthcare.
By sharing these stories, EP PerMed aims to inspire the scientific community, engage stakeholders, and inform the public about the value of investing in personalised medicine research. Each success story reflects the dedication of international, multi-stakeholder consortia working together to improve patient care and advance the field of personalised medicine, aligning with EP PerMed’s commitment to fostering impactful, collaborative innovation.
CLL-CLUE: Personalising Treatment for Europe’s Most Common Leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in Europe, and despite significant medical advances, it remains incurable. The CLL-CLUE project utilised Functional Precision Medicine (FPM) to improve the treatment outcome of CLL. The consortium used a specific targeted drug (a PI3K inhibitor) as a model to understand how these therapies change the internal communication lines, or cell signaling, within leukaemia cells.
PRETWINSCREEN: Advancing Personalised Prenatal Care for Twin Pregnancies
Twin pregnancies carry higher risks, yet standard prenatal care often doesn’t reflect their unique needs. The PRETWINSCREEN project developed new, tailored screening tools to improve early detection of complications and personalise care — helping clinicians better protect both mothers and babies.
PARADISE: A New Way of Predicting Autoimmune Disease Relapses
The PARADISE project ambitious goal is to develop a deployable, personalised predictive tool that accurately assesses an individual’s immune system activation. By tailoring medication dosages – or safely discontinuing them altogether – PARADISE aims to redefine how autoimmune diseases are managed, significantly improving patient care and quality of life.
